Skip to content

Deep Brain Stimulation in Treatment Resistant Alcoholism

Deep Brain Stimulation in Treatment Resistant Alcoholism - DeBraSTRA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00003206
Enrollment
30
Registered
2012-07-10
Start date
2013-07-12
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F10.2

Interventions

Group 1: Sham(Placebo)-Stimulation during first 6 months Group 2: Verum-Stimulation during first 6 months

Sponsors

Klinik für Psychiatrie und Psychotherapie
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
25 Years to 60 Years

Inclusion criteria

Inclusion criteria: - Inpatient detoxification with abstinence of at least two weeks prior to surgery - No withdrawal syndrome during the one week prior to surgery - Alcohol addiction for at least 10 years according to DSM-IV/ICD-10 - Minimum of 30 drinks on average per week over a consecutive 30-day period in a three-month period prior to initiation of abstinence - Treatment resistance as defined by unsuccessful long term inpatient rehabilitation treatment of at least six months, or 2 or more rehabilitation treatments discontinued by the patient, and at least one pharmacological therapy for at least 2 months with one of the anti-craving drugs acamprosate, naltrexone or disulfiram - Educational level of at least nine years of school - Phone number of patient for phone interviews.

Exclusion criteria

Exclusion criteria: - Females - Other DSM-IV axis I disorder - Abuse or addiction to other substances (other than nicotine) with a positive drug test on a urine screen - Antisocial personality (score of > 20) on the psychopathy check list PCL-R - Visible brain damage in a CT or MRI scan - Severe neurological or medical illness - General contraindication to surgery and/or anesthesia - below 80% of medians of battery of neuropsychological tests: HAWIE-R, MWTB, LPS-3, (verbal and non-verbal intelligence tests to ensure that patients are able to give informed consent) - Illiterate or unable to read and write German

Design outcomes

Primary

MeasureTime frame
Primary efficacy endpoint: time to relapse within first 6 months after randomization

Secondary

MeasureTime frame
what: Key secondary endpoint(s): 1. Overall alcohol consumption (Drinks per drinking day and percent heavy drinking days assessed with Form 90). 2.Alcohol Craving (attentional bias as experimental lab paradigm), Clinical Craving scales (OCDS; AUQ),,Consequences of drinking (DRInC), ADS, CGI, GAS, SCL-90, WHO-QoL, Hautzinger list of pleasant activities) When: during the course of entire study How: check what

Countries

Germany

Contacts

Public ContactUlf J. Mueller

Klinik für Psychiatrie und Psychotherapie

ulf.mueller@med.ovgu.de0391-6714235

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026